Loss of TET2 and TET3 in regulatory T cells unleashes effector function

Yue, Xiaojing; Lio, Chan-Wang J.; Samaniego-Castruita, Daniela; Li, Xiang; Rao, Anjana

doi:10.1038/s41467-019-09541-y

Download PDF

Article
Open access
Published: 01 May 2019

Loss of TET2 and TET3 in regulatory T cells unleashes effector function

Xiaojing Yue¹,
Chan-Wang J. Lio ORCID: orcid.org/0000-0003-3876-6741¹,
Daniela Samaniego-Castruita¹,
Xiang Li¹ &
…
Anjana Rao^1,2,3

Nature Communications volume 10, Article number: 2011 (2019) Cite this article

10k Accesses
99 Citations
25 Altmetric
Metrics details

Subjects

Abstract

TET enzymes oxidize 5-methylcytosine to 5-hydroxymethylcytosine and other oxidized methylcytosines in DNA. Here we examine the role of TET proteins in regulatory T (Treg) cells. Tet2/3^fl/flFoxp3^Cre mice lacking Tet2 and Tet3 in Treg cells develop inflammatory disease, and Treg cells from these mice show altered expression of Treg signature genes and upregulation of genes involved in cell cycle, DNA damage and cancer. In littermate mice with severe inflammation, both CD4⁺Foxp3⁺ and CD4⁺Foxp3⁻ cells show strong skewing towards Tfh/Th17 phenotypes. Wild-type Treg cells in mixed bone marrow chimeras and in Tet2/3^fl/flFoxp3^WT/Cre heterozygous female mice are unable to rescue the aberrant properties of Tet2/3^fl/flFoxp3^Cre Treg cells. Treg cells from Tet2/3^fl/flFoxp3^Cre mice tend to lose Foxp3 expression, and transfer of total CD4⁺ T cells isolated from Tet2/3^fl/flFoxp3^Cre mice could elicit inflammatory disease in fully immunocompetent mice. Together, these data indicate that Tet2 and Tet3 are guardians of Treg cell stability and immune homeostasis.

FOXO1 is a master regulator of memory programming in CAR T cells

Article Open access 10 April 2024

FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy

Article Open access 10 April 2024

Depleting myeloid-biased haematopoietic stem cells rejuvenates aged immunity

Article 27 March 2024

Introduction

Regulatory T (Treg) cells are a distinct lineage of CD4⁺ T lymphocytes that prevent autoimmunity against self-antigens and maintain immune homeostasis^1,2. The lineage specification, development, and suppressive function of Treg cells are controlled by Foxp3, an X-chromosome-encoded transcription factor that is the most specific marker distinguishing Treg cells from other T helper cell populations³. Foxp3-expressing Treg cells have been reported to be stable in both steady state and inflammatory conditions in vivo⁴, but a fraction of Treg cells show unstable Foxp3 expression^5,6. Fate mapping experiments have shown that many of these Treg cells are “ex-Treg” cells that derive from Foxp3-expressing Treg cells that subsequently lose Foxp3 expression⁵, but some may be conventional T cells that transiently express Foxp3, thus representing a minor population of uncommitted Treg cells⁶. Moreover, Treg-specific genetic ablation of many gene products—including cell surface proteins such as neuropilin1, transcription factors such as NR4A, signaling molecules such as PTEN, and epigenetic regulators such as EZH2—results in instability of Treg Foxp3 expression and/or loss of suppressive function^7,8,9,10,11.

Epigenetic changes, including histone modifications, DNA methylation and chromatin accessibility, play a critical role in establishing and maintaining the Treg cell lineage³. The best studied of these epigenetic changes is DNA demethylation at various Treg-specific demethylated regions (TSDRs), including two “conserved non-coding sequences” (CNS) CNS1 and CNS2 within the Foxp3 locus^12,13. The stability of Foxp3 expression is closely linked to the demethylated status of CNS1 and CNS2^12,13, while Treg-specific gene expression and optimal Treg function are linked to the DNA methylation status of other relevant TSDRs. Thus, it is important to understand how DNA methylation is regulated at these elements, and how it in turn controls the stability and function of Treg cells.

TET family proteins are Fe(II) and 2-oxoglutarate-dependent dioxygenases that catalyze oxidation of the methyl group of 5-methylcytosine (5mC) in DNA to 5-hydroxymethylcytosine (5hmC) and the further oxidized products 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC)^{14,15,16,17,18}. These modified bases are intermediates in DNA demethylation^19,20,21. TET proteins and DNA modification exert a pervasive influence on immune/hematopoietic cell development and function. Acute deletion of Tet2 and Tet3 in hematopoietic stem cells induced the rapid development of an aggressive and fully-penetrant myeloid leukemia in adult mice²². Deletion of Tet2 and Tet3 by Mb1-Cre in early B cells resulted in developmental blockade at the pro-B to pre-B cell transition due to a defect in immunoglobulin light chain rearrangement^23,24. Deletion of Tet2 and Tet3 in T cells mediated by CD4-Cre led to an antigen-driven expansion of invariant NKT (iNKT) cells, which developed rapidly into CD1d-restricted iNKT cell lymphoma²⁵. Treg cells in this Tet2/3-deficient mouse strain displayed unstable Foxp3 expression, concomitantly with DNA hypermethylation at CNS1, CNS2, and other TSDRs¹². Combined deletion of Tet1 and Tet2 also resulted in CNS2 hypermethylation and impaired Treg cell differentiation and function²⁶.

Our previous study on the role of TET proteins in Treg cells¹² was complicated by the iNKT cell expansion occurring in the same mouse strain, in which Tet gene deletion was mediated by CD4-Cre^12,25. Here, we used a mouse strain in which Tet2 and Tet3 deficiency were targeted specifically to Foxp3-expressing Treg cells using Foxp3^YFP−Cre (Foxp3^Cre). Tet2/3^fl/flFoxp3^Cre mice develop an inflammatory disease with splenomegaly and leukocyte infiltration into lung, and CD4⁺Foxp3⁺ Treg cells, CD4⁺Foxp3⁻ and CD8⁺ T cells in these mice display an activated phenotype. Tet2/3^fl/flFoxp3^Cre Treg cells show dysregulation of Treg signature genes and genes related to cell cycle, DNA damage and cancer compared to WT Treg cells. Perplexingly, a very similar inflammatory disease develops in Tet2/3^fl/flFoxp3^WT/Cre heterozygous female mice and in mixed bone marrow chimeras in which lethally irradiated mice were reconstituted with a 1:1 mixture of wild-type and Tet2/3^fl/flFoxp3^Cre bone marrow cells, indicating that wild-type Treg cells was not sufficient to rescue the inflammatory phenotype observed in Tet2/3 DKO mice. Fate-mapping experiments showed that Treg cells from Tet2/3^fl/flFoxp3^Cre DKO mice are more prone to lose Foxp3 expression and become “ex-Treg” cells. Furthermore, transfer of total CD4⁺ T cells from Tet2/3^fl/flFoxp3^Cre DKO mice, which contained these ex-Treg cells, elicits inflammatory disease in immunocompetent mice. Thus, TET deficiency in Treg cells resulted in a dominant inflammatory disease, in which the inflammatory phenotype was driven, at least in part, by ex-Treg cells that acquired effector function. Our data emphasize that TET proteins are essential for maintenance of Treg cell stability and immune homeostasis in mice.

Results

Tet2/3-deficiency in Treg cells leads to T cell activation

To investigate the role of TET proteins in Treg cells, we crossed mice carrying LoxP-flanked Tet2 and Tet3 alleles (Tet2/3^fl/fl) with Foxp3^YFP-Cre (Foxp3^Cre) mice in which YFP-Cre fusion protein is knocked into the 3’ UTR of the Foxp3 gene²⁷, to generate mice with Treg-specific deletion of Tet2 and Tet3 (Tet2/3^fl/flFoxp3^Cre mice). Tet2 and Tet3 mRNAs were specifically deleted in CD4⁺YFP⁺ Treg cells but not in CD4⁺YFP^- conventional T cells (Supplementary Fig. 1a). Mice lacking Tet2 and Tet3 in Treg cells did not survive past 8–22 weeks of age (Fig. 1a), although a fraction of male mice survived slightly longer than female mice (Supplementary Fig. 1b). Tet2/3^fl/flFoxp3^Cre mice displayed splenomegaly and lymphadenopathy, primarily of mesenteric lymph nodes (mLNs, Supplementary Fig. 1c), as evidenced by an increased cellularity (Fig. 1b). The slight increase in cellularity observed in peripheral lymph nodes (pLNs) did not reach statistical significance (Fig. 1b). Histological analysis revealed disrupted splenic architecture in Tet2/3^fl/flFoxp3^Cre mice with expansion of the white pulp areas, accompanied by leukocyte infiltration into the lung (Supplementary Fig. 1d). Examination of peripheral blood showed an increase in neutrophils and a decrease in lymphocytes, which were within the normal range; and the concentration of red blood cells appeared normal (Supplementary Table 1). Tet2/3^fl/flFoxp3^Cre mice had significantly higher titers of anti-dsDNA antibodies in the serum compared to WT mice (Supplementary Fig. 2a), suggesting altered self-tolerance. In addition, the titer of serum IgG2b isotype was significantly higher in Tet2/3^fl/flFoxp3^Cre mice than in WT mice, and there was a tendency towards increased titers of serum IgG1, IgG2a, IgG3, and IgM, which correlated with the severity of disease development in the mice. In contrast, the titer of serum IgA appeared slightly decreased in Tet2/3^fl/flFoxp3^Cre mice compared to WT mice (Supplementary Fig. 2b).

Tet2/3^fl/flFoxp3^Cre mice displayed a significant reduction in the percentages of CD4⁺ and CD8⁺ T cells in spleen and pLNs (Fig. 1c, left panel, Supplementary Fig. 3a), but the numbers of CD4⁺ and CD8⁺ T cells were roughly maintained except for an increase in CD4⁺ T cell numbers in the spleen (Fig. 1c, right panel). The percentage of CD62L^hiCD44^lo naïve cells was dramatically decreased in both CD4⁺ and CD8⁺ T cell populations, indicating that the majority of the T cells were activated or became memory cells (Fig. 1d, e and Supplementary Fig. 3b). We also observed a reduction in the percentage of B cells and an increase in the percentage of CD11b⁺Gr1⁺ myeloid cells (Supplementary Fig. 4).

Dysregulated cell surface phenotype of Tet2/3 DKO Treg cells

We next examined the phenotypic features of Tet2/3-deficient Treg cells. The frequency of Foxp3⁺ Treg cells (as a percentage of total CD4⁺ T cells) was increased in spleen, as well as in peripheral and mesenteric lymph nodes of Tet2/3^fl/flFoxp3^Cre mice relative to that of WT mice (Fig. 2a, b). Despite the increase in frequency, Tet2/3 DKO Treg cells had lower expression levels of CD25 (IL-2 receptor α chain), a signature surface cytokine receptor of Treg and activated T cells; they also displayed a significant decrease in the expression of neuropilin-1 (Nrp1), an important mediator of Treg homeostasis and function²⁸, in both spleen and pLNs (Fig. 2c). Flow cytometric analysis revealed varying degrees of increased expression and/or an increased proportion of cells expressing the transcription factor Helios (Ikzf2) and the surface proteins ICOS, CD103, GITR, CTLA-4, and PD-1 in Tet2/3 DKO compared to those in WT Treg cells, especially in the spleen; but similar expression of CD127, IL-7 receptor α chain (Fig. 2d). Both Nrp1 and Helios have been reported to be markers of thymic-derived Treg cells and were used to distinguish thymic-derived Treg cells from peripherally-induced Treg cells;^29,30,31 however, the reliability of these markers is still controversial^32,33. The expression of Nrp1 was downregulated in Treg cells from mLNs in Tet2/3^fl/flFoxp3^Cre mice compared to that of WT mice, while the expression of Helios was increased (Supplementary Fig. 3c). The chemokine receptor CCR7, which is important for the migration and function of Treg cells³⁴, was also significantly downregulated in Treg cells from Tet2/3^fl/flFoxp3^Cre compared to WT mice (Supplementary Fig. 3d). Moreover, compared to their WT counterparts, Treg cells from Tet2/3^fl/flFoxp3^Cre mice showed a decreased proportion of CD62L^hiCD44^lo cells (Fig. 2e) and a higher frequency of CD69⁺ recently activated cells (Fig. 2f), indicating that Tet2 and Tet3 deficiency in Treg cells results in an activated phenotype and dysregulated expression of multiple Treg activation and phenotypic molecules. The increased frequency and activation status of Treg cells that we observe in Tet2/3^fl/flFoxp3^Cre mice is also commonly observed in mice with Treg perturbations, and may reflect a compensatory increase in Treg cell numbers observed under conditions of insufficient overall Treg cell function^8,35.

Decreased long term suppression by Tet2/3 DKO Treg cells

To investigate the in vivo function of Treg cells isolated from Tet2/3^fl/flFoxp3^Cre mice, we used a mouse model in which we attempted to correct the scurfy phenotype. Scurfy mice lack Treg cells due to a natural frame-shift mutation in the Foxp3 gene that abrogates Foxp3 protein expression³⁶. Transfer of peripheral CD4⁺ T cells from scurfy male mice into Rag1-deficient recipients leads to an expansion of autoreactive scurfy CD4⁺ T cells and severe autoimmune inflammation due to a lack of effective Treg cell suppression; both features can be suppressed by co-transfer of congenically marked WT Treg cells³⁷. We transferred 5 × 10⁵ scurfy CD4⁺ T cells (CD45.1⁺) into Rag1-deficient recipient mice together with 1 × 10⁵ Treg cells from CD45.2⁺ mice, either WT Foxp3^Cre or Tet2/3^fl/flFoxp3^Cre mice (Supplementary Fig. 5a). In this short-term in vivo suppression assay, Treg cells isolated from Tet2/3^fl/flFoxp3^Cre mice suppressed the expansion of scurfy CD4⁺ T cells to almost the same extent as Treg cells isolated from WT mice, as evidenced by decreased expansion of CD45.1⁺ scurfy cells measured in spleen and lymph nodes 4–5 weeks after adoptive transfer (percentages, Supplementary Fig. 5b; total cell numbers, Supplementary Fig. 5c). As we previously observed for Treg cells from Tet2/3^fl/flCD4^Cre mice¹², Treg cells isolated from Tet2/3^fl/flFoxp3^Cre mice were more likely to lose Foxp3 expression compared to WT control Treg cells (Supplementary Fig. 5b, c).

To examine Treg function over a longer time course, we transferred bone marrow cells from scurfy mice into sublethally irradiated Rag1^-/- recipient mice, alone or together with bone marrow cells from WT or Tet2/3^fl/flFoxp3^Cre mice (Supplementary Fig. 5d, e). As expected³⁸, recipient mice receiving scurfy bone marrow cells alone started to lose weight at 4 weeks and succumbed 6–7 weeks after transfer. Co-transfer of WT bone marrow cells suppressed scurfy cell expansion and protected the recipient mice from death, whereas co-transfer of Tet2/3 DKO bone marrow cells failed to protect the recipient mice, which lost weight after 9 weeks and died at 11–13 weeks after transfer (Supplementary Fig. 5d, e). Together, these data indicate that Tet2/3-deficient Treg cells from Tet2/3^fl/flFoxp3^Cre mice have normal in vivo suppressive function in the short-term that is not sustained in the long-term.

Moderate hypermethylation of CNS2 in Tet2/3 DKO Treg cells

The expression of Foxp3 during Treg cell differentiation is regulated by three conserved noncoding sequence (CNS) elements located in the first intron of the Foxp3 gene³⁹. Among these, CNS1 and CNS2 have been shown to control the stability of Foxp3 expression in a manner linked to the DNA modification status of these elements^12,13. Given that TET proteins catalyze the process of loss of 5mC at CNS1 and CNS2 during Treg development in vivo¹², we examined the DNA modification status at Foxp3 CNS1 and CNS2 in CD4⁺CD25⁺YFP⁺ peripheral Treg cells isolated from male WT or Tet2/3^fl/flFoxp3^Cre mice using bisulfite-sequencing (BS-seq) (Supplementary Fig. 6a). The results clearly show impaired DNA demethylation (assessed as loss of 5mC) in Foxp3 CNS1 and CNS2 in Treg cells isolated from Tet2/3^fl/flFoxp3^Cre mice; however, this impairment was less pronounce (i.e., 5mC + 5hmC levels assessed by BS-seq were lower) than we had previously observed in Treg cells isolated from Tet2/3^fl/flCD4^Cre mice (Fig. 3a, b). This result is likely to reflect the chronological order of CD4^Cre versus Foxp3^Cre expression: CD4^Cre mediates Tet2 and Tet3 deletion at an earlier developmental stage compared to Foxp3^Cre. Consistent with this difference, CpG sites #6 and #9-11 in the CNS2 region, which have already initiated the process of loss of 5mC at the Foxp3⁺CD25⁻ precursor stage¹², were efficiently demethylated in Tet2/3^fl/flFoxp3^Cre Treg cells. We also examined several other regulatory regions that show Treg-specific hypomethylation: Il2ra intron1a, Tnfrsf18 exon5, Ikzf4 intron1b, and Ctla4 exon2⁴⁰. The DNA modification status at Il2ra intron1a, Tnfrsf18 exon5 and Ikzf4 intron1b showed similar pattern compare to that of Foxp3 CNS1 and CNS2 regions: DNA demethylation was impaired in Treg cells isolated from Tet2/3^fl/flFoxp3^Cre mice, but to a lesser extent, compare to that in Treg cells isolated from Tet2/3^fl/flCD4^Cre mice (Fig. 3c–e). However, at Ctla4 exon2, the levels of impairment in DNA demethylation were similar regardless of whether Treg cells were isolated from Tet2/3^fl/flFoxp3^Cre mice or Tet2/3^fl/flCD4^Cre mice (Fig. 3f).

Altered gene expression patterns in Tet2/3 DKO Treg cells

To further investigate the molecular mechanisms by which TET proteins control Treg cell identity and function, we compared the transcriptional profiles of CD4⁺YFP⁺ Treg cells sorted from 14-weeks-old Foxp3^Cre WT and Tet2/3^fl/flFoxp3^Cre DKO mice (2 biological replicates each, isolated from pooled spleen and pLNs) (Supplementary Fig. 6b). We isolated RNA from two Tet2/3^fl/flFoxp3^Cre DKO littermates with the assumption that these mice would have comparable phenotypes. However, when sacrificed, one of these mice (labeled with an asterisk: DKO*) clearly showed more severe splenomegaly than its littermate (DKO). This difference was obvious in principal component analysis (PCA) of the RNA-seq data: the biological replicates of WT cells, whether Treg or CD4⁺Foxp3^– cells, clustered closely together, while those from Treg and CD4⁺Foxp3^– cells obtained from the two 14-weeks-old Tet2/3^fl/flFoxp3^Cre littermates were not as closely aligned (Supplementary Fig. 7a). As expected, both Treg and CD4⁺Foxp3^– T cells from the Tet2/3^fl/flFoxp3^Cre mouse with less severe splenomegaly more closely resembled the corresponding WT cells, whereas cells from the mouse with more severe splenomegaly were less similar to WT (Supplementary Fig. 7a). Nevertheless, scatter plots of the data showed reasonably good correlation between the two replicates from Tet2/3 DKO Treg and CD4⁺Foxp3^– T cells (0. 92 and 0.90, respectively), although the correlation between the WT replicates was stronger (0.94 and 0.93, respectively) (Supplementary Fig. 7b, c). Based on these data, we averaged the two DKO replicates for subsequent analyses.

Based on a cut-off of FDR (false discovery rate) ≤ 0.05 and a fold change ≥ 1.5, 1565 genes were differentially expressed, with 1156 genes being upregulated and 409 genes being downregulated in Tet2/3 DKO Treg cells compared to WT Treg cells (Fig. 4a). Seventy-six Treg signature genes were differentially expressed (Supplementary Data 1) and a selected subset (Foxp3, Nrp1, Il1rl1, Prg4, Dnahc7b, and Klrg1) are pointed out in the mean average (MA) plot (Fig. 4a). Ingenuity pathway analysis (IPA) of the differentially expressed genes showed that Tet2/3 deficiency in Treg cells affected three main categories of canonical pathways (Fig. 4b and Supplementary Data 2): genes involved in DNA damage, DNA repair (Brca1, Atm, Rad50), and cell cycle (Cdkn1a, Cdkn2a, Hipk2) (green bars); genes implicated in immune cell function such as the antigen presentation pathway (H2-Aa, H2-Ab, and H2-Eb1), Th1 and Th2 activation pathways, etc (blue bars); and genes related to molecular mechanisms of cancer (orange bars).

A recent study demonstrated that microbial-mediated inflammatory signals were critical for myeloid expansion of Tet2-deficient mice⁴¹. Therefore, we used RNA-seq to examine the transcriptional profiles of CD4⁺YFP⁺ Treg cells sorted from mLNs of 14-week-old WT and Tet2/3^fl/flFoxp3^Cre mice (3 biological replicates each) (Supplementary Fig. 6b). There was good correlation among the biological replicates (Supplementary Table 2). Based on a cut-off of FDR (false discovery rate) ≤ 0.05 and a fold change ≥ 1.5, 2073 genes were differentially expressed, with 1449 genes being upregulated and 624 genes being downregulated in Tet2/3 DKO Treg cells compared to WT Treg cells (Supplementary Fig. 8a). A handful of them overlapped with the differentially expressed genes from Tet2/3 DKO vs WT Treg cells isolated from pooled spleen and pLNs (Supplementary Fig. 8b). IPA analysis of the differentially expressed genes indicated that similar canonical pathways were affected, including genes involved in cell cycle, DNA damage, immune cell function, and cancer development (Supplementary Fig. 8c and Supplementary Data 3).

The majority of cell cycle-related genes were upregulated in Tet2/3 DKO Treg cells (see heatmap of Fig. 4c and Supplementary Fig. 8d), prompting us to assess the proliferation of Tet2/3 DKO Treg cells in vivo. We injected WT and Tet2/3^fl/flFoxp3^Cre mice with BrdU, a thymidine analog that is incorporated into newly synthesized DNA during replication, and analyzed Treg cells 24 h later. Indeed, Tet2/3 DKO Treg cells incorporated significantly more BrdU compared to WT Treg cells (Fig. 4d). The genes involved in DNA damage pathways also prompted us to examine the level of phosphorylated histone H2A.X (γH2AX), an early marker of DNA damage⁴², by flow cytometry. In fact, the MFI (mean fluorescent intensity) of γH2AX staining was significantly increased in both Treg cells and CD4⁺Foxp3⁻ cells in spleen and mLN isolated from Tet2/3^fl/flFoxp3^Cre compared to WT mice (Supplementary Fig. 9). But we did not observe any increase in the level of active caspase-3, an early stage apoptosis marker, in Treg cells from Tet2/3^fl/flFoxp3^Cre mice compared to WT mice (Supplementary Fig. 10). Analysis of the TCR repertoire using RNA-seq reads mapping to the CDR3 region at Tcrb showed greater clonal expansion in both Treg cells and CD4⁺Foxp3⁻ cells isolated from Tet2/3^fl/flFoxp3^Cre compared to WT mice (Supplementary Fig. 11 and Supplementary Data 4 and 5), suggesting antigen-driven expansion.

Compared to WT mice, expression of genes involved in Tfh differentiation, including Gzmb, Pdcd1, Bcl6, Maf, Cxcr5, and Il21, was unaltered or only mildly increased in Treg cells isolated from the Tet2/3^fl/flFoxp3^Cre mouse with moderate splenomegaly (DKO), but markedly increased in Treg cells isolated from the littermate mouse with more severe splenomegaly (DKO*) (Fig. 4e, left panel). Genes related to Tfh and Th17 cell differentiation (Il17a, Il17f, Rorc) in CD4⁺Foxp3^– T cells displayed a similar trend (Fig. 4e, right panel), indicating that both CD4⁺Foxp3⁺ Treg cells and CD4⁺Foxp³⁻ T cells from Tet2/3^fl/flFoxp3^Cre mice displayed skewing to Tfh and/or Th17 lineages in a manner that correlated directly with disease severity. The skewed Tfh and/or Th17 lineages were also observed in Treg cells and CD4⁺Foxp3^– T cells isolated from mLN of Tet2/3^fl/flFoxp3^Cre mice (Supplementary Fig. 8e).

In WT mice at steady state, fewer than 5% of CD4⁺TCRβ⁺ T cells from spleen and mLNs stained positive for the Tfh signature molecules CXCR5 and PD-1, but this percentage was much higher in the spleen and mLNs of Tet2/3^fl/flFoxp3^Cre mice (Fig. 4f). In addition, spleen and mLNs of Tet2/3^fl/flFoxp3^Cre mice had more germinal center (GC) B cells, as judged by expression of the GC signature markers GL7 and CD95 (Fig. 4g).

WT Tregs fail to control autoimmunity in Tet-deficient mice

Foxp3 is encoded on the X-chromosome, hence due to random X-inactivation, Tet2/3^fl/fl female mice that are heterozygous for Foxp3^Cre (Foxp3^WT/Cre) should harbor both Tet2/3-deleted Treg cells (Foxp3^Cre-positive) and WT Treg cells (Foxp3^Cre-negative). Thus, the presence of WT Treg cells should in theory prevent the mice from developing any autoimmune disease. Surprisingly, we found that Tet2/3^fl/flFoxp3^WT/Cre female mice also developed lymphoproliferative disease beginning as early as 15 weeks of age, and all mice succumbed by the age of 38 weeks (Fig. 5a). As expected, the total cellularity of the spleen from Tet2/3^fl/flFoxp3^WT/Cre female mice was significantly increased compared to WT female mice (Fig. 5b).

To confirm this observation independently, we generated mixed bone marrow chimeras by adoptively co-transferring WT (CD45.1⁺) bone marrow cells together with bone marrow cells (CD45.2⁺) isolated from WT or Tet2/3^fl/flFoxp3^Cre DKO mice at 1:1 ratio into lethally irradiated CD45.1⁺ WT mice (Fig. 5c). Chimeric mice given either WT or Tet2/3^fl/flFoxp3^Cre DKO bone marrow cells were similar and appeared relatively normal at 14–16 weeks after adoptive transfer (Supplementary Fig. 12). However at 18–20 weeks after adoptive transfer, DKO bone marrow chimeras developed splenomegaly compared to WT chimeras and showed a significant increase of total cellularity in the spleen (Fig. 5d).

Notably, CD45.2⁺ cells in mixed chimeras with Tet2/3^fl/flFoxp3^Cre DKO bone marrow showed considerably higher capacity for expansion compared to CD45.2⁺ cells in WT mixed bone marrow chimeras (Fig. 5e, f, leftmost panels). In the DKO chimeric mice, the percentage of CD4⁺CD45.2⁺ T cells was significantly higher than expected, with over 80% of CD4⁺CD45.2⁺ T cells observed in one DKO chimeric mouse; however, the percentage of CD8⁺ T cells was strongly decreased (Fig. 5e, second panels; Fig. 5f, second and third panels). The frequency of Foxp3⁺ cells in the CD45.2⁺CD4⁺ population varied widely in the DKO mixed chimeras, with some chimeras displaying a frequency as high as 60–70%, while others showed fewer than 10% of CD45.2⁺CD4⁺Foxp3⁺ cells (Fig. 5e, middle panel; Fig. 5f, last panel), suggesting that Treg cells in the DKO chimeras could manifest unstable Foxp3 expression. Moreover, both CD4⁺Foxp3⁺ and CD4⁺Foxp3⁻ DKO cells in the chimeric mice showed an activated/memory phenotype, with a strong decrease in the proportion of “naïve” CD62L^hiCD44^lo cells (Fig. 5e, last two panels). Together these data indicate that the loss of T regulatory function in Tet2/3 DKO Treg cells is dominant, and cannot be rescued or prevented in the presence of WT Treg cells.

Unstable Foxp3 expression in Tet2/3 DKO Treg cells

Although Foxp3⁺ Treg cells are generally stable and are marked by sustained expression of Foxp3, they may lose Foxp3 expression under certain conditions and develop into cells resembling effector T cells, designated “ex-Treg” cells⁵. To examine whether Tet2/3-deficient Treg cells indeed lose Foxp3 expression and become ex-Treg effector cells, we introduced the Rosa26-YFP^LSL allele⁴³ into Tet2/3^fl/flFoxp3^Cre mice. In the LSL (LoxP-STOP-LoxP) cassette, a strong transcriptional stop site is flanked by two LoxP sites and inserted into the Rosa26 locus ahead of the cDNA sequence encoding YFP, ensuring that YFP expression is turned on only in Cre-expressing cells. Since YFP expression from the Rosa26 locus is much brighter than YFP expression from the YFP-Cre fusion protein introduced into the 3’ UTR of the Foxp3 gene, cells expressing YFP from the Rosa26 locus can be easily distinguished from cells expressing the YFP-Cre fusion protein encoded in the Foxp3 gene⁴⁴ (Fig. 6a, where intermediate YFP expression derives from the YFP-Cre fusion protein whereas high YFP expression derives from the Rosa26 fate mapping allele). Analysis of CD4⁺ T cells from spleen and mLNs of Tet2/3^fl/flFoxp3^CreRosa26-YFP^LSL mice showed clearly that a much higher proportion of Rosa-YFP^high cells—cells that had turned on Cre from the Foxp3 gene, and thus had been Treg cells earlier in their developmental history—had lost Foxp3 expression and turned into ex-Treg cells, compared to Rosa-YFP^high cells from heterozygous Tet2^+/flTet3^fl/flFoxp3^CreRosa26-YFP mice (Fig. 6a, b). Further confirming the existence of ex-Treg cells in Tet2/3^fl/flFoxp3^Cre mice, we showed by quantitative real-time PCR, as well as RNA-seq that Tet2 and Tet3 mRNAs were both greatly reduced in expression in CD4⁺YFP⁻ cells isolated from Tet2/3^fl/flFoxp3^Cre compared to WT mice (qPCR, Supplementary Fig. 13a; number of normalized reads mapping to the deleted exons; Supplementary Fig. 13b–c). Taken together with the data presented in the previous sections, this finding suggests strongly that a substantial fraction of the activated CD4⁺YFP⁻ T cells in Tet2/3^fl/flFoxp3^Cre mice (Fig. 5e, f) are ex-Treg cells that have lost suppressive function and acquired deleterious effector function.

Tet2/3 DKO CD4⁺ T cells elicits disease in healthy mice

To test the above hypothesis of deleterious effector function acquired by ex-Treg cells from Tet2/3^fl/flFoxp3^Cre mice, we asked whether total CD4⁺ T cells from Tet2/3^fl/flFoxp3^Cre mice, which contain ex-Treg cells, as well as bystander activated CD4⁺ T cells, could elicit disease when transferred into healthy immunocompetent recipient mice. We transferred purified CD4⁺ T cells (5 × 10⁶; purity > 98.5%) from spleen and pLNs into fully immunocompetent (non-irradiated) congenic CD45.1⁺ recipient mice (Fig. 7a). All the recipients developed enlarged spleen and lymph nodes and developed disease 7–10 weeks after transfer (Fig. 7b). Tet2/3 DKO CD4⁺ T cells expanded 3–50 fold, from the starting transferred population of 5 million cells to as many as 250 million cells (Fig. 7b). The percentage of Foxp3⁺ cells after expansion of the transferred CD4⁺ population varied from mouse to mouse, with three mice showing high-level Foxp3 expression (mouse example 1 in Fig. 7c), and the others showing low to no expression of Foxp3 (mouse example 2 in Fig. 7c). We observed a compensatory expression of Foxp3⁺ cells in CD45.1⁺ host cells in each individual (Fig. 7b, c). Moreover, both CD4⁺Foxp3⁺ host Treg cells and CD4⁺Foxp3⁻ host cells displayed activated phenotype with low levels of CD62L expression and high levels of CD44 expression (Fig. 7c, Host Cells). Together these data suggest that Tet2/3 DKO CD4⁺ T cells contained the cell population responsible for transferring the diseases to immunocompetent mice. These might be ex-Treg effector cells, host CD4⁺ T cells that became activated and converted to effector cells, or both.

Discussion

Here, we investigated the role of two epigenetic regulators, the methylcytosine oxidases Tet2 and Tet3, in Treg function. Mice with Treg-specific deletion of Tet2 and Tet3 (Tet2/3^fl/flFoxp3^Cre mice) display defective Treg function and develop an inflammatory disease characterized by splenomegaly and leukocyte infiltration into tissues. TET loss-of-function in developing Tet2/3^fl/flFoxp3^Cre Treg cells led to increased methylation (5mC + 5hmC) at the Foxp3 CNS1 and CNS2 enhancers compared to wild-type Treg cells resulting in decreased stability of Foxp3 expression and impaired Treg cell function. Notably, both ex-Treg cells and conventional CD4⁺ and CD8⁺ T cells in Tet2/3^fl/flFoxp3^Cre DKO mice developed an aberrant dominant effector phenotype, which could not be suppressed by the presence of wild-type Treg cells in Tet2/3^fl/flFoxp3^WT/Cre heterozygous females or in mixed bone marrow chimeras. Our data emphasize the essential role of TET-mediated epigenetic modifications not only in maintaining the demethylated status of the Foxp3 CNS1 and CNS2 enhancers—thereby stabilizing Foxp3 expression, specifying Treg cell lineage and conferring stable Treg identity—but also in preventing indirectly the acquisition of aberrant effector function by bystander CD4⁺ and CD8⁺ T cells with otherwise normal TET function.

Individual or dual deletion of TET genes can both be deleterious for Treg cell^12,26,45 (and this study), B cell²³ and myeloid function^{22,46,47,48,49,50,51}. The phenotypic variability is potentially related to the animal facility in which the mice are housed⁴¹. Myeloid expansion in Tet2-deficient mice has been attributed to the influence of cytokines such as IL-6 produced in response to gut microbiota, since it is eliminated or greatly attenuated if the mice are housed in a germ-free facility⁴¹. Similarly, the large increase in the cellularity of mesenteric lymph nodes compared to peripheral lymph nodes in our 12–16 week-old Tet2/3^fl/flFoxp3^Cre mice, as well as the increased clonality of both Foxp3⁺ Treg cells and CD4⁺Foxp3^– T cells (ex-Treg cells and/or activated CD4⁺ bystander T cells), suggests a role for recognition of microbial or other antigens. Thus, the effects of TET loss-of-function appear most striking when TET-deficient cells are subjected to stimulation, through antigen recognition²⁵, cytokine stimulation¹¹, or the influence of the microbiota as discussed above⁴¹.

By fate-mapping experiments, Foxp3 expression in Treg cells from Tet2/3^fl/flFoxp3^Cre mice was considerably less stable than Foxp3 expression in Treg cells from control mice (Fig. 6). Treg cells from Tet2/3^fl/flFoxp3^Cre mice were more prone to lose Foxp3 expression, and also showed dysregulated expression of many Treg signature genes including Cd25, Nrp1, and Il1rl1. Notably, the presence of wild-type Treg cells in Tet2/3^fl/flFoxp3^WT/Cre heterozygous females or mixed bone marrow chimeras was not sufficient to suppress the aberrant inflammation observed in Tet2/3^fl/flFoxp3^Cre mice, moreover, transfer of total CD4⁺ T cells from Tet2/3^fl/flFoxp3^Cre mice into immunocompetent recipient mice unexpectedly resulted in efficient transfer of the inflammatory disease. In both mixed bone marrow chimeras and CD4⁺ T cell transfer experiments, Foxp3⁺ cells from Tet2/3^fl/flFoxp3^Cre mice expanded somewhat more extensively than control cells in an early phase in which they maintained almost normal suppressive function; later, they lost Foxp3 expression and suppressive function but acquired effector function, leading to the accumulation of effector ex-Treg cells, as well as activated bystander CD4⁺ and CD8⁺ T cells as the mice aged. Thus, loss of TET function in Treg cells of Tet2/3^fl/flFoxp3^Cre mice results in a paradoxical dominant disease, in which defective TET-deficient Treg cells lose Foxp3 expression and suppressor function on the one hand, and convert to ex-Treg cells with dominant effector function on the other hand.

In addition to simply losing suppressive function, ex-Treg cells appear to be prone to acquire effector function⁵². The underlying mechanisms are not yet completely clear, but it is known that mice with Treg perturbations frequently compensate for insufficiency of T regulatory function by becoming hyperproliferative and hyperactivated^8,35. For instance, ex-Treg cells arising as a result of deficiency in the mTOR-signaling regulator TSC1 produce increased levels of IL-17 and acquire Th17 effector features under inflammatory conditions;⁵³ and neuropilin1-deficient Treg cells produce high levels of IFNγ, which feeds back to suppress Treg cell function¹¹. In our case, we have shown that Tet2/3 deficiency leads to increased expression of genes related to Tfh and/or Th17 cell differentiation, both in CD4⁺Foxp3^– T cells which include both ex-Treg cells and CD4⁺ bystander cells, and in CD4⁺Foxp3⁺ Treg cells, in a manner that correlated directly with disease severity.

Our data emphasize the critical role of TET proteins in the maintenance of stable Foxp3 expression and the integrity of Treg gene expression and function. Absence of TET proteins in Treg cells sets off a cascade of events that begins with increased DNA methylation of CNS1 and CNS2 and unstable Foxp3 expression, both facilitated by cell division occurring as a result of antigen and cytokine stimulation; and continues into compromised suppressor function and acquisition of effector function by ex-Treg cells, as well as bystander T cells. The aberrant acquisition of these dysregulated phenotypes eventually results in a fatal inflammatory/ lymphoproliferative disease.

Methods

Mice

B6.129(Cg)-Foxp3^{tm4(YFP/icre)Ayr}/J (Foxp3^Cre, strain 016959), B6.SJL-Ptprc^aPepc^b/BoyJ (CD45.1 congenic mice, strain 002014), B6.129S7-Rag1^tm1Mom/J (Rag1^−/− mice, strain 002216), and B6.Cg-Foxp3^sf/J (B6-scurfy mice, strain 004088) were obtained from Jackson Laboratory. Tet2^fl/flTet3^fl/flFoxp3^Cre mice were generated in our laboratory by crossing Tet2^fl/flTet3^fl/f with Foxp3^Cre mice. For the fate-mapping experiments, Tet2^+/flTet3^fl/flFoxp3^Cre or Tet2^fl/flTet3^+/flFoxp3^Cre female mice were crossed with Tet2^fl/flTet3^fl/flRosa26-YFP⁺ male mice to generate Tet2^fl/flTet3^fl/flFoxp3^CreRosa26-YFP⁺ male mice for further analysis. All mice were on the B6 background and maintained in a specific pathogen-free animal facility in the La Jolla Institute for Immunology. Age of the mice used for each experiment was stated in the figure legends. All cell or mouse irradiation procedures were performed using RS2000 Biological Irradiator (Rad Source Technologies, Inc.) All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee of the La Jolla Institute for Immunology and were conducted in accordance with institutional guidelines.

Cell preparation and flow cytometry

Single-cell suspensions were prepared from spleen, peripheral lymph nodes, and mesenteric lymph nodes for staining or cell sorting. For analysis of T cell compartments and Treg cell features, single-cell suspensions were stained with anti-mouse antibodies against the following (Clone name, conjugated fluorescence, dilution, manufacturer and catalog number shown in brackets): CD4 (RM4-5, PerCP-Cy5.5, 1:200, Biolegend, #100540; GK1.5, APC, 1:200, Biolegend, #100412; RM4-5, BV570, 1:200, Biolegend, #100541; GK1.5, BV421, 1:200, Biolegend, #100437), CD8 (53-6.7, PE-Cy7, 1:200, Biolegend, #100722; 53-6.7, AF700, 1:200, Biolegend, #100730), CD62L (MEL-14, BV421, 1:400, Biolegend, #104436; MEL-14, APC, 1:200, Biolegend, #104412), CD25 (PC61, APC, 1:200, Biolegend, #102012), CD44 (IM7, PE, 1:200, Biolegend, #103008; IM7, PerCP-Cy5.5, 1:200, Biolegend, #103032), CD45.1 (A20, PE-Cy7, 1:200, Biolegend, #110730), CD45.2 (104, PE-Dazzle594, 1:200, Biolegend, #109846; 104, BV421, 1:200, Biolegend, #109831), Nrp1 (3E12, BV421, 1:200, Biolegend, #145209), ICOS (C398.4 A, AF488, 1:200, Biolegend, #313514), CD103 (2E7, FITC, 1:200, Biolegend, #121419), GITR (YGITR765, PE-Cy7, 1:200, Biolegend, #120222), PD1 (29 F.1A12, PE-Cy7, 1:200, Biolegend, #135216), CD127 (A7R34, BV421, 1:200, Biolegend, #135027), CD69 (H1.2F3, APC, 1:200, Biolegend, #104514), B220 (RA3-6B2, APC, 1:200, Biolegend, #103212), Gr1 (RB6-8C5, PE, 1:400, Biolegend, #108408), CD11b (M1/70, PerCP-Cy5.5, 1:200, Biolegend, #101228), CCR7 (4B12, BV421, 1:100, Biolegend, #120119). Anti-mouse CCR7 staining was performed at 37 °C for 30 min. For analysis of Tfh and germinal center B cells, single-cell suspensions were stained with anti-mouse antibodies TCRβ (H57-597, APC, 1:200, Biolegend, #109212), CD19 (6D5, APC, 1:200, Biolegend, #115512), CXCR5 (L138D7, BV421, 1:100, Biolegend, #145511), PD1 (29 F.1A12, PE-Cy7, 1:200, Biolegend, #135216), GL7 (GL7, Pacific Blue, 1:200, Biolegend, #144613) and CD95 (Fas, Jo2, PE-Cy7, 1:200, BD Biosciences, #557653). For intracellular staining, cells were surface-stained and then stained with anti-Foxp3 (FJK-16S, PE, 1:100, eBioscience, #12-5773-82), anti-active caspase-3 (C92-605, PE, 20 μl per assay, BD Biosciences, #550821), anti-Helios (22F6, APC, 1:100, Biolegend, #137221), anti-CTLA4 (UC104.89, APC, 1:100, Biolegend, #106309), and anti-H2A.X phosphorylated (Ser139, 2F3, APC, 1:100, Biolegend, #613415) antibodies using the Foxp3 Fixation/Permeabilization kit (eBioscience, #00-5523-00) and analyzed by flow cytometry on LSR-II and LSR Fortessa.

BrdU incorporation assay

Mice were injected with 1 mg of BrdU (100 μl of 100 mg/ml stock solution) intraperitoneally. 24 h later, mice were sacrificed and the cells from spleen and peripheral lymph nodes were stained for surface markers and then for BrdU according to the manufacturer’s protocol (BD Pharmingen, APC BrdU flow kit 552598).

Anti-dsDNA antibody ELISA

Anti-dsDNA autoantibodies in the serum from Foxp3^Cre WT and Tet2/3^fl/flFoxp3^Cre mice (11–16 weeks-old) were measured with kit from Alpha Diagnostic International according to the manufacturer’s protocol (ELISA Kit 5110).

LEGENDplex mouse immunoglobulin isotyping panel

The serum immunoglobulin levels were measured with LEGENDplex Mouse Immunoglobulin Isotyping Panel according to the manufacturer’s protocol (Biolegend, 740493).

Analysis of peripheral bloods from Tet2/3 ^fl/fl Foxp3 ^Cre mice

Peripheral bloods from WT and Tet2/3^fl/flFoxp3^Cre DKO mice (12–14 weeks-old) were collected into tubes pretreated with EDTA (BD Biosciences, 365974). Hematological parameters including the concentrations of white blood cells (WBCs), red blood cells (RBCs), and platelets were analyzed by Hemavet 950FS (Drew Scientific).

Generation of mixed bone marrow chimeras

Bone marrow cells were obtained from tibia and fibula from Foxp3^Cre WT mice, Tet2/3^fl/flFoxp3^Cre mice and CD45.1 congenic mice. Erythrocytes and mature T cells were then depleted from the bone marrow cells using MACS LS columns. The purified cells (2.5 × 10⁶) from Foxp3^Cre WT and Tet2/3^fl/flFoxp3^Cre mice were then mixed together with cells (2.5 × 10⁶) isolated from tibia and fibula from CD45.1 congenic mice at 1:1 ratio and transferred intravenously (i.v.) into lethally irradiated CD45.1 congenic mice. Reconstituted mice were then sacrificed for analysis 14–20 weeks after adoptive transfer of bone marrow cells.

Scurfy CD4⁺ T cell adoptive transfer

Scurfy CD4⁺ T cells were isolated from spleen and peripheral lymph nodes from male Scurfy mice and purified using Dynabeads (Life Tech, purity > 98%). 5 × 10⁵ CD45.1⁺CD4⁺ scurfy T cells were injected into Rag1-deficient mice alone or mixed with 1 × 10⁵ Treg cells isolated from Foxp3^Cre WT or Tet2/3^fl/flFoxp3^Cre mice. Four to 5 weeks after adoptive transfer, the percentage of CD45.1⁺CD4⁺ cells and CD45.2⁺ CD4⁺Foxp3⁺ cells were analyzed by flow cytometry. Alternatively, we used bone marrow cells from scurfy mice, Foxp3^Cre WT or Tet2/3^fl/flFoxp3^Cre mice for the adoptive transfer.

Tet2/3 DKO CD4⁺ T cell adoptive transfer

Total CD4⁺ T cells were isolated from spleen and peripheral lymph nodes from CD45.2⁺ Tet2/3^fl/flFoxp3^Cre mice and double purified using Dynabeads (Life Tech, purity > 98.5%). 5 × 10⁶ CD4⁺ T cells were adoptively transferred into immunocompetent congenic mice and analyzed for 7–10 weeks after adoptive transfer. As a control, total CD4⁺ T cells isolated from CD45.2⁺ Foxp3^Cre WT mice were also transferred into immunocompetent congenic mice, which did not show any cell expansion.

Bisulfite (BS) sequencing

DNA samples were treated with sodium bisulfite for 4 h (MethylCode Bisulfite Conversion Kit, MECOV50, Invitrogen). The PCR amplicons were generated using PyroMark PCR kit (Qiagen), and quantified using Quant-iT PicoGreen dsDNA reagent (Invitrogen). PCR amplicons were then used for library preparation using NEBNext DNA Library Modules for Illumina platform (NEB). The final libraries were quantified using KAPA library quantification kit for Illumina (KAPA Biosystems), and sequenced on Miseq (300 bp, paired end, Illumina). The data are based on thousands of sequence reads per amplicon. The bisulfite sequencing reads were mapped to mouse genome mm9 using the Bismark mapping tool. The mapping was done using the paired-end Bowtie2 backend with the following parameter values: -I 0 –X 600 –N 0. For each of the samples, the “bismark_methylation_extractor” script in the Bismark package was used to extract the numbers of times each cytosine within the amplicons was converted. These counts were used to calculate the proportions for each cytosine to be non-methylated (or formylmethylated/carboxylmethylated) or methylated (or hydroxymethylated).

RNA-seq library preparation

Total RNA were isolated from CD4⁺YFP⁺ (Foxp3⁺) Treg cells and CD4⁺YFP^- (Foxp3⁻) T cells (from pooled spleen and pLNs in Fig. 4 or from mLNs in Supplementary Fig. 8) from Foxp3^Cre WT mice and Tet2/3^fl/flFoxp3^Cre DKO mice (14-weeks-old) using RNeasy plus mini kit (Qiagen). RNA-sequencing libraries were prepared using Truseq stranded mRNA kit (Illumina) according to the manufacture’s protocol and sequenced at the La Jolla Institute sequencing core using Illumina HiSeq2500 single end 50 bp platform.

RNA-seq and TCR-seq analysis

RNA-seq data were mapped against the UCSC mouse genome mm9 using TopHat2⁵⁴ (v2.1.1) with the following parameters “-p 16 -N 2 --max-multihits 1 --read-gap-length 1 --transcriptome-index” and the RefSeq gene annotation was obtained from the UCSC genome Bioinformatics database. The number of reads mapping to each gene was counted using featureCounts⁵⁵ (subread-1.4.3-p1) with the following parameters “-g gene_name –s 2”. Differentially expressed genes (DEGs) between WT and Tet2/3 DKO cell types were determined using the Bioconductor package DESeq2⁵⁶ with adjusted P value < 0.05 and a fold change threshold of > 1.5 or < 0.67. And genes with total counts < 1 in the sum of all conditions were removed from the analysis. Canonical pathway analysis was performed using Ingenuity Pathway Analysis software (license for La Jolla Institute).

TCR sequences were retrieved from RNA-Seq data sets, and the frequency of TCRβ chain clonotypes (CDR3 regions) was determined using MiXCR⁵⁷ (mixcr-1.7–2.1) package for RNA-seq analysis with the default parameters “align –l TCR –s mmu –p rnaseq -OallowPartialAlignments = true”. Two rounds of contig assembly were performed by employing the “assemblePartial” function; extension of incomplete TCR CDR3s with uniquely determined V and J genes using germline sequences was done using the “extendAlignments” function; assembly and export of the clonotypes was performed using the “assemble” and the “exportClones” (--preset min -fraction -targets -vHits -dHits -jHits -vAlignments -dAlignments -jAlignments) functions, respectively.

Quantitative real-time PCR

Total RNA was isolated using RNeasy plus mini kit (Qiagen); cDNA was synthesized using SuperScript III reverse transcriptase (Thermo Fisher). Quantitative real-time PCR was performed using FastStart Universal SYBR Green Master mix (Roche) on a StepOnePlus real-time PCR machine (Thermo Fisher). Gene expression was normalized to Hprt. Primers used to detect the expression levels of Tet2, Tet3, and Foxp3 are as following:

Tet2 forward primer: AACCTGGCTACTGTCATTGCTCCA

Tet2 reverse primer: ATGTTCTGCTGGTCTCTGTGGGAA

Tet3 forward primer: GTCTCCCCAGTCCTACCTCCG

Tet3 reverse primer: GTCAGTGCCCCACGCTTCA

Foxp3 forward primer: GGCCCTTCTCCAGGACAGA

Foxp3 reverse primer: GCTGATCATGGCTGGGTTGT

Hprt forward primer: CTGGTGAAAAGGACCTCTCG

Hprt reverse primer: TGAAGTACTCATTATAGTCAAGGGCA

Histology

Lungs, livers, and spleens were isolated from 12–14-week-old Tet2/3^fl/flFoxp3^Cre DKO mice and littermate controls. Samples were fixed using 10% formalin overnight, preserved in 70% ethanol and embedded in paraffin. The paraffin blocks were then cut and sections were stained with haematoxylin and eosin (H&E).

Statistics

P values from unpaired two-tailed Student’s t test were used for all the statistical comparisons between different groups and data were displayed as mean ± s.d. (Prism). P values are denoted in corresponding figures as: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Reporting summary

Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The authors declare that all data supporting the findings of this study are available within the article and its Supplementary information files or from the corresponding author upon reasonable request. RNA-seq data have been deposited in the Gene Expression Omnibus database under accession number GSE113694. A reporting summary for this Article is available as a Supplementary Information file.

References

Josefowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531–564 (2012).
Article CAS Google Scholar
Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775–787 (2008).
Article CAS Google Scholar
Li, X. & Zheng, Y. Regulatory T cell identity: formation and maintenance. Trends Immunol. 36, 344–353 (2015).
Article CAS Google Scholar
Rubtsov, Y. P. et al. Stability of the regulatory T cell lineage in vivo. Science 329, 1667–1671 (2010).
Article ADS CAS Google Scholar
Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000–1007 (2009).
Article CAS Google Scholar
Miyao, T. et al. Plasticity of Foxp3( + ) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 36, 262–275 (2012).
Article CAS Google Scholar
Sekiya, T. et al. Suppression of Th2 and Tfh immune reactions by Nr4a receptors in mature T reg cells. J. Exp. Med. 212, 1623–1640 (2015).
Article CAS Google Scholar
DuPage, M. et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity 42, 227–238 (2015).
Article CAS Google Scholar
Shrestha, S. et al. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat. Immunol. 16, 178–187 (2015).
Article CAS Google Scholar
Huynh, A. et al. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat. Immunol. 16, 188–196 (2015).
Article CAS Google Scholar
Overacre-Delgoffe, A. E. et al. Interferon-gamma drives treg fragility to promote anti-tumor immunity. Cell 169, 1130–1141 e1111 (2017).
Article CAS Google Scholar
Yue, X. et al. Control of Foxp3 stability through modulation of TET activity. J. Exp. Med. 213, 377–397 (2016).
Article CAS Google Scholar
Floess, S. et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS. Biol. 5, e38 (2007).
Article Google Scholar
Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009).
Article ADS CAS Google Scholar
Iyer, L. M., Tahiliani, M., Rao, A. & Aravind, L. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 8, 1698–1710 (2009).
Article CAS Google Scholar
Ito, S. et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333, 1300–1303 (2011).
Article ADS CAS Google Scholar
He, Y. F. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303–1307 (2011).
Article ADS CAS Google Scholar
Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839–843 (2010).
Article ADS CAS Google Scholar
Wu, X. & Zhang, Y. TET-mediated active DNA demethylation: mechanism, function and beyond. Nat. Rev. Genet. 18, 517–534 (2017).
Article CAS Google Scholar
Tsagaratou, A., Lio, C. J., Yue, X. & Rao, A. TET methylcytosine oxidases in T Cell and B cell development and function. Front. Immunol. 8, 220 (2017).
Article Google Scholar
Pastor, W. A., Aravind, L. & Rao, A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell. Biol. 14, 341–356 (2013).
Article CAS Google Scholar
An, J. et al. Acute loss of TET function results in aggressive myeloid cancer in mice. Nat. Commun. 6, 10071 (2015).
Article ADS CAS Google Scholar
Lio, C. W., et al. Tet2 and Tet3 cooperate with B-lineage transcription factors to regulate DNA modification and chromatin accessibility. eLife 5, e18290 (2016).
Orlanski, S. et al. Tissue-specific DNA demethylation is required for proper B-cell differentiation and function. Proc. Natl Acad. Sci. USA 113, 5018–5023 (2016).
Article ADS CAS Google Scholar
Tsagaratou, A. et al. TET proteins regulate the lineage specification and TCR-mediated expansion of iNKT cells. Nat. Immunol. 18, 45–53 (2017).
Article CAS Google Scholar
Yang, R. et al. Hydrogen Sulfide Promotes Tet1- and Tet2-mediated Foxp3 demethylation to drive regulatory T Cell differentiation and maintain immune homeostasis. Immunity 43, 251–263 (2015).
Article CAS Google Scholar
Rubtsov, Y. P. et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28, 546–558 (2008).
Article CAS Google Scholar
Delgoffe, G. M. et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501, 252–256 (2013).
Article ADS CAS Google Scholar
Yadav, M. et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J. Exp. Med. 209, S1711–S1719 (2012).
Article Google Scholar
Weiss, J. M. et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3 + T reg cells. J. Exp. Med. 209, S1721 (2012).
Article Google Scholar
Thornton, A. M. et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3 + T regulatory cells. J. Immunol. 184, 3433–3441 (2010).
Article CAS Google Scholar
Gottschalk, R. A., Corse, E. & Allison, J. P. Expression of Helios in peripherally induced Foxp3 + regulatory T cells. J. Immunol. 188, 976–980 (2012).
Article CAS Google Scholar
Singh, K., Hjort, M., Thorvaldson, L. & Sandler, S. Concomitant analysis of Helios and Neuropilin-1 as a marker to detect thymic derived regulatory T cells in naive mice. Sci. Rep. 5, 7767 (2015).
Article ADS CAS Google Scholar
Schneider, M. A. et al. CCR7 is required for the in vivo function of CD4 + CD25 + regulatory T cells. J. Exp. Med. 204, 735–745 (2007).
Article CAS Google Scholar
Pierson, W. et al. Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3( + ) regulatory T cells. Nat. Immunol. 14, 959–965 (2013).
Article CAS Google Scholar
Brunkow, M. E. et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27, 68–73 (2001).
Article CAS Google Scholar
Choi, J. M. et al. Cell-permeable Foxp3 protein alleviates autoimmune disease associated with inflammatory bowel disease and allergic airway inflammation. Proc. Natl Acad. Sci. USA 107, 18575–18580 (2010).
Article ADS CAS Google Scholar
Ouyang, W. et al. Foxo proteins cooperatively control the differentiation of Foxp3 + regulatory T cells. Nat. Immunol. 11, 618–627 (2010).
Article CAS Google Scholar
Zheng, Y. et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463, 808–812 (2010).
Article ADS CAS Google Scholar
Ohkura, N. et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37, 785–799 (2012).
Article CAS Google Scholar
Meisel, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557, 580–584 (2018).
Article ADS CAS Google Scholar
Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe to play with knives. Mol. Cell. 40, 179–204 (2010).
Article CAS Google Scholar
Srinivas, S. et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1, 4 (2001).
Article CAS Google Scholar
Wu, D. et al. Lkb1 maintains Treg cell lineage identity. Nat. Commun. 8, 15876 (2017).
Article ADS CAS Google Scholar
Nair, V. S. & Oh, K. I. Down-regulation of Tet2 prevents TSDR demethylation in IL2 deficient regulatory T cells. Biochem. Biophys. Res. Commun. 450, 918–924 (2014).
Article CAS Google Scholar
Ko, M. et al. TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol. Rev. 263, 6–21 (2015).
Article CAS Google Scholar
Li, Z. et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118, 4509–4518 (2011).
Article CAS Google Scholar
Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11–24 (2011).
Article CAS Google Scholar
Rasmussen, K. D. et al. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes. Dev. 29, 910–922 (2015).
Article CAS Google Scholar
Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25–38 (2011).
Article CAS Google Scholar
Ko, M. et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl Acad. Sci. USA 108, 14566–14571 (2011).
Article ADS CAS Google Scholar
Sawant, D. V. & Vignali, D. A. Once a Treg, always a Treg? Immunol. Rev. 259, 173–191 (2014).
Article CAS Google Scholar
Park, Y. et al. TSC1 regulates the balance between effector and regulatory T. Cells J. Cli. Invest. 123, 5165–5178 (2013).
Article CAS Google Scholar
Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
Article Google Scholar
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
Article CAS Google Scholar
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Article Google Scholar
Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381 (2015).
Article CAS Google Scholar

Download references

Acknowledgements

We thank members of the Rao laboratory for suggestions and discussions. We thank Cheryl Kim, Denise Hinz, Lara Boggeman, and Robin Simmons at the La Jolla Institute Flow Cytometry facility for help with cell sorting experiments; Jeremy Day of the La Jolla Institute Sequencing facility for help with next-generation sequencing and Dr. Zbigniew Mikulski and Margie Chadwell of the La Jolla Institute Microscopy and Histology facility for help with histological and microscopic analysis; and the Histology Core at the University of California at San Diego Moores Cancer Center. We thank Dr. Nissi Varki from University of California at San Diego for help with histology analysis. This work was supported by National Institutes of Health (NIH) R01 grants R35 CA210043 and AI 12858901 (to A.R.). FACSAria II Cell Sorter was acquired through the Shared Instrumentation Grant (SIG) Program S10 RR027366 and Hiseq2500 was funded by S10OD016262. C.W.L. was supported by Irvington Postdoctoral Fellowship from the Cancer Research Institute. D.S.C. is a graduate student in the UCSD Biology Program and is supported by a CONACYT/UCMEXUS fellowship from Mexico. X.L. was supported by a postdoctoral Fellowship from CIRM UCSD Interdisciplinary Stem Cell Research and Training Grant II (TG2-01154).

Author information

Authors and Affiliations

Division of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA
Xiaojing Yue, Chan-Wang J. Lio, Daniela Samaniego-Castruita, Xiang Li & Anjana Rao
Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92037, USA
Anjana Rao
Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA
Anjana Rao

Authors

Xiaojing Yue
View author publications
You can also search for this author in PubMed Google Scholar
Chan-Wang J. Lio
View author publications
You can also search for this author in PubMed Google Scholar
Daniela Samaniego-Castruita
View author publications
You can also search for this author in PubMed Google Scholar
Xiang Li
View author publications
You can also search for this author in PubMed Google Scholar
Anjana Rao
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

A.R., X.Y., and C.W.L. conceived the project. A.R. supervised project planning and execution. X.Y. and X.L. performed experiments. D.S.C. performed bioinformatic analyses of RNA-seq data. C.W.L. provided input for experimental design and critically evaluated the manuscript. A.R. and X.Y. wrote the manuscript.

Corresponding author

Correspondence to Anjana Rao.

Ethics declarations

Competing interests

A.R. is a member of the Scientific Advisory Board of Cambridge EpiGenetix, Ltd., Cambridge, UK. The remaining authors declare no competing interests.

Additional information

Journal peer review information: Nature Communications thanks Andrew Wells and the other anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Data 1

Supplementary Data 2

Supplementary Data 3

Supplementary Data 4

Supplementary Data 5

Reporting Summary

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Yue, X., Lio, CW.J., Samaniego-Castruita, D. et al. Loss of TET2 and TET3 in regulatory T cells unleashes effector function. Nat Commun 10, 2011 (2019). https://doi.org/10.1038/s41467-019-09541-y

Download citation

Received: 30 April 2018
Accepted: 15 March 2019
Published: 01 May 2019
DOI: https://doi.org/10.1038/s41467-019-09541-y

This article is cited by

Breaking tolerance: the autoimmune aspect of atherosclerosis
- Amir Khan
- Payel Roy
- Klaus Ley
Nature Reviews Immunology (2024)
Ferritin heavy chain supports stability and function of the regulatory T cell lineage
- Qian Wu
- Ana Rita Carlos
- Miguel P Soares
The EMBO Journal (2024)
TET2 inhibits the proliferation and metastasis of lung adenocarcinoma cells via activation of the cGAS-STING signalling pathway
- Gui Cheng
- Jun Wu
- Jingting Jiang
BMC Cancer (2023)
Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics
- Fengyun Zhong
- Yilin Lin
- Zhanlong Shen
British Journal of Cancer (2023)
TET2 and TET3 loss disrupts small intestine differentiation and homeostasis
- Ihab Ansari
- Llorenç Solé-Boldo
- Yehudit Bergman
Nature Communications (2023)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.